MCID: NRN001
MIFTS: 47

Neuroendocrine Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Neuroendocrine Carcinoma

MalaCards integrated aliases for Neuroendocrine Carcinoma:

Name: Neuroendocrine Carcinoma 12 15
Carcinoma, Neuroendocrine 44
Carcinoma Neuroendocrine 54
Neuroendocrine Cancer 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1800
MeSH 44 D018278
NCIt 50 C3773
SNOMED-CT 67 55937004
UMLS 70 C0206695

Summaries for Neuroendocrine Carcinoma

Disease Ontology : 12 A carcinoma that derives from neuroendocrine cells.

MalaCards based summary : Neuroendocrine Carcinoma, also known as carcinoma, neuroendocrine, is related to pulmonary large cell neuroendocrine carcinoma and primary hepatic neuroendocrine carcinoma. An important gene associated with Neuroendocrine Carcinoma is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and Central carbon metabolism in cancer. The drugs Etoposide and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, breast and cervix, and related phenotypes are nervous system and neoplasm

Wikipedia : 73 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Related Diseases for Neuroendocrine Carcinoma

Diseases related to Neuroendocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 877)
# Related Disease Score Top Affiliating Genes
1 pulmonary large cell neuroendocrine carcinoma 32.7 SYP NCAM1 CHGA ASCL1
2 primary hepatic neuroendocrine carcinoma 32.6 SYP CHGA
3 ovarian large-cell neuroendocrine carcinoma 32.2 SYP NCAM1 KRT7 KRT20 ENO2 CHGA
4 urinary bladder small cell neuroendocrine carcinoma 32.0 SYP NCAM1 KRT7 KRT20 GRP ENO2
5 pancreatic endocrine carcinoma 32.0 SYP SST NCAM1 GAST CHGA
6 gallbladder small cell carcinoma 31.9 SYP NCAM1 KRT7 ENO2 CHGA
7 large cell neuroendocrine carcinoma 31.8 SYP PDGFRA NKX2-1 NCAM1 KRT7 KRT20
8 rare tumor 31.5 SST KIT
9 merkel cell carcinoma 31.3 SYP SST PDGFRA PAX5 NKX2-1 NCAM1
10 adenocarcinoma 31.2 PTEN NKX2-1 MUC1 KRT7 KRT20 KIT
11 carcinoid syndrome 31.2 SYP SST ENO2 CHGA CALCA
12 squamous cell carcinoma 31.0 PTEN MUC1 KRT7 KRT19 FGFR4
13 thyroid carcinoma 31.0 PTEN NKX2-1 CALCA
14 olfactory neuroblastoma 30.9 SYP NKX2-1 ENO2 CHGA
15 cervix small cell carcinoma 30.9 SYP ENO2 CHGA
16 sinonasal undifferentiated carcinoma 30.8 SYP MUC1 ENO2
17 adenoma 30.8 SYP SST MUC1 KRT7 KRT20 CHGA
18 appendix adenocarcinoma 30.8 SYP KRT7 KRT20 CHGA
19 cervical adenocarcinoma 30.8 PTEN KRT7 KRT20
20 carcinosarcoma 30.8 PTEN MUC1 KRT7 KIT
21 tubular adenocarcinoma 30.8 SYP MUC1 KRT7 KRT20 ENO2 CHGA
22 suppression of tumorigenicity 12 30.8 SYP PTEN CHGA
23 intrahepatic cholangiocarcinoma 30.7 MUC1 KRT7 KRT20 KRT19
24 spindle cell sarcoma 30.7 MUC1 KRT7 KIT
25 multiple endocrine neoplasia, type i 30.7 SYP SST GAST CHGA
26 signet ring cell adenocarcinoma 30.7 MUC1 KRT7 KRT20 CHGA
27 multiple endocrine neoplasia 30.7 SST GAST CHGA CALCA
28 atrophic gastritis 30.7 SST GAST CHGA
29 gastric adenocarcinoma 30.7 PTEN KRT20 KIT GAST
30 transitional cell carcinoma 30.7 PTEN KRT7 KRT20 KRT19 ENO2
31 lung large cell carcinoma 30.7 SYP NKX2-1 NCAM1 CHGA
32 skin benign neoplasm 30.7 KRT7 KRT20 ENO2
33 villous adenoma 30.6 SST MUC1 KRT7 KRT20
34 lung cancer susceptibility 3 30.6 NKX2-1 MUC1 KRT7 KRT20 KRT19 FGFR4
35 eyelid carcinoma 30.6 KRT7 KRT20
36 cholangiocarcinoma 30.6 NCAM1 MUC1 KRT7 KRT20 KRT19
37 endocervical adenocarcinoma 30.5 MUC1 KRT7 KRT20
38 neurilemmoma 30.5 PDGFRA MUC1 KIT ENO2
39 ampulla of vater benign neoplasm 30.5 SYP SST ENO2 CHGA
40 islet cell tumor 30.5 SYP SST GAST CHGA CALCA
41 acinar cell carcinoma 30.5 KRT7 GAST CHGA
42 papillary adenocarcinoma 30.4 NKX2-1 MUC1 KRT7 KRT19
43 mature teratoma 30.4 SYP KRT7 KIT ENO2
44 external ear carcinoma 30.4 KRT7 CALCA
45 cystadenoma 30.4 SYP PTEN MUC1 KRT7 KRT20 CHGA
46 colorectal adenocarcinoma 30.4 PTEN NKX2-1 MUC1 KRT7 KRT20 KIT
47 thyroid gland medullary carcinoma 30.4 SYP SST NKX2-1 GAST CHGA CALCA
48 mucinous adenocarcinoma 30.4 NKX2-1 MUC1 KRT7 KRT20 KRT19 KIT
49 ectopic cushing syndrome 30.3 SST CHGA CALCA
50 intestinal obstruction 30.3 KRT7 KRT20 KIT

Graphical network of the top 20 diseases related to Neuroendocrine Carcinoma:



Diseases related to Neuroendocrine Carcinoma

Symptoms & Phenotypes for Neuroendocrine Carcinoma

MGI Mouse Phenotypes related to Neuroendocrine Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.07 ASCL1 CHGA ENO2 GRP KIT KRT19
2 neoplasm MP:0002006 9.92 FGFR4 GAST KIT KRT19 NKX2-1 PAX5
3 no phenotypic analysis MP:0003012 9.7 ASCL1 CHGA KIT KRT19 NKX2-1 PDGFRA
4 normal MP:0002873 9.61 ASCL1 KIT KRT19 NKX2-1 PAX5 PDGFRA
5 respiratory system MP:0005388 9.28 ASCL1 ENO2 FGFR4 GRP KIT KRT19

Drugs & Therapeutics for Neuroendocrine Carcinoma

Drugs for Neuroendocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
2
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
3 Etoposide phosphate Phase 2, Phase 3
4
Gemcitabine Approved Phase 2 95058-81-4 60750
5
Loperamide Approved Phase 1, Phase 2 53179-11-6 3955
6
Melphalan Approved Phase 2 148-82-3 4053 460612
7
Pertuzumab Approved Phase 2 380610-27-5, 145040-37-5 2540
8
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
9
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
10
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
11
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
12
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
13
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 5330286 11431660
14
Nintedanib Approved Phase 2 656247-17-5 56843413
15
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6, 75614-87-8 774
16
Trifluridine Approved, Investigational Phase 2 70-00-8 6256
17
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
18
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
19
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
20
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
21
Methyltestosterone Approved Phase 2 58-18-4 6010
22
Testosterone Approved, Investigational Phase 2 58-22-0 6013
23
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0
24
Testosterone enanthate Approved Phase 2 315-37-7 9416
25
Lenvatinib Approved, Investigational Phase 2 417716-92-8
26
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
27
Bevacizumab Approved, Investigational Phase 2 216974-75-3
28
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
29
Pasireotide Approved Phase 2 396091-73-9 9941444
30
Iodine Approved, Investigational Phase 2 7553-56-2 807
31
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
32
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
33
Olaparib Approved Phase 2 763113-22-0 23725625
34
Ipilimumab Approved Phase 2 477202-00-9
35
nivolumab Approved Phase 2 946414-94-4
36
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
37
Ponatinib Approved, Investigational Phase 2 943319-70-8 24826799
38
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
39
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
40
Fluorouracil Approved Phase 2 51-21-8 3385
41
leucovorin Approved Phase 2 58-05-9 6006
42
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
43
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
44
Lenograstim Approved, Investigational Phase 2 135968-09-1
45
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
46
Pancrelipase Approved, Investigational Phase 2 53608-75-6
47
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
48
Lithium carbonate Approved Phase 2 554-13-2
49
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
50
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3

Interventional clinical trials:

(show top 50) (show all 181)
# Name Status NCT ID Phase Drugs
1 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Active, not recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
3 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
4 Phase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma Recruiting NCT03992911 Phase 2, Phase 3 Simmtecan, 5-FU and l-LV;Toripalimab;Etoposide, Cisplatin;Etoposide, Carboplatin
5 A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Recruiting NCT04211337 Phase 3 Selpercatinib;Cabozantinib;Vandetanib
6 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
7 A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib Active, not recruiting NCT01298323 Phase 3 Vandetanib
8 Phase II Study of FOLFIRI as the Seconde Line Chemotherapy in Advanced or Metastatic Neuroendocrine Carcinoma Unknown status NCT03168607 Phase 2 FOLFIRI Protocol
9 Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study Unknown status NCT02943798 Phase 2 etoposide plus carboplatin;Paclitaxel plus carboplatin
10 Phase II Study of SOX as the Seconde Line Chemotherapy in Advanced or Metastatic Neuroendocrine Carcinoma Unknown status NCT03279614 Phase 2 SOX
11 Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors Unknown status NCT01203306 Phase 2 bevacizumab + octreotide LAR + capecitabine
12 A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas Unknown status NCT02215447 Phase 2 NAB paclitaxel;Carboplatin
13 Randomized Phase II Study of Octreotide LAR as Maintenance Treatment After First-line Chemotherapy for Patients With Unresectable or Metastatic Gastro-entero-pancreatic or Esophageal Neuroendocrine Carcinomas Unknown status NCT02409849 Phase 2 Octreotide lar
14 A Phase II Clinical Trial of Cisplatin + Gemcitabine HCl (GEM) + Low-Dose Metronomic Interferon-a (IFN-a) Combined With Fever-Range Whole-Body Thermal Therapy (FR-WB-TT) in Patients With Metastatic/or Locally Advanced Malignancies (Small-Cell Lung Cancer, Neuroendocrine Cancer, Gastric Cancer) Unknown status NCT00178698 Phase 2 Cisplatin, Gemcitabine, Interferon-a
15 An Open Label, Single-Centre, Pilot Study for Radiosensitization of Everolimus With External Beam Radiotherapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis Unknown status NCT02205515 Phase 1, Phase 2 Everolimus
16 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
17 The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer Unknown status NCT01739634 Phase 1, Phase 2 CASAD
18 A Phase II Clinical Trial of Irinotecan (CPT-11) in Patients With Advanced High Grade Neuroendocrine Tumors Completed NCT00004922 Phase 2 irinotecan hydrochloride
19 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver Completed NCT00019786 Phase 2 isolated perfusion;melphalan
20 Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors Completed NCT01396382 Phase 2
21 Continuous 5-fluorouracil Infusion Plus Long Acting Octreotide in Advanced Well Differentiated Neuroendocrine Carcinomas. A Phase II Trial of the Piemonte Oncology Network. Completed NCT00953394 Phase 2 continuous 5 fluouracil infusion plus long-acting octreotide
22 Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Sandostatin for Patients With Advanced Neuroendocrine Cancers. Completed NCT01121939 Phase 2 Bevacizumab;Pertuzumab;Sandostatin LAR® Depot
23 Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study Completed NCT02113800 Phase 2 Everolimus (Afinitor®)
24 TheraSphere for the Treatment of Liver Metastases: An Open Label Trial of TheraSphere in Patients With Liver Metastases From Primary Colorectal Cancer, Neuroendocrine Cancer or Non-colorectal/Non-neuroendocrine Cancer Completed NCT00511862 Phase 2
25 A Phase II Study of G3139 (Genasense ™) in Patients With Merkel Cell Carcinoma Completed NCT00079131 Phase 2
26 A Phase II Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00388063 Phase 2 Atiprimod
27 A Phase II Trial of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma) Completed NCT00003549 Phase 2 CMF regimen;cyclophosphamide;fluorouracil;methotrexate
28 Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients Completed NCT01873248 Phase 1, Phase 2 68Ga-DOTATATE
29 Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma Completed NCT00193531 Phase 2 Paclitaxel;Carboplatin;Etoposide
30 Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell) Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
31 A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma) Completed NCT00068783 Phase 2 imatinib mesylate
32 68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors Completed NCT01879657 Phase 1, Phase 2 68Ga-DOTATATE PET scan
33 Everolimus and Temozolomide as 1-line Treatment in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) With a Ki67 of 20-55% Completed NCT02248012 Phase 2 Everolimus , temozolomide
34 SAMSUND MEDICAL CENTER Completed NCT03147404 Phase 2 Avelumab
35 Exploratory Study of Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma (AVF3961s) (CRAD001C2481) Completed NCT00607113 Phase 2 Avastin;RAD001
36 A Phase II Open-Label Extension Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00663429 Phase 2 Atiprimod
37 Multicenter 3-arm Trial to Evaluate the Efficacy and Safety of Pasireotide LAR or Everolimus Alone or in Combination in Patients With Well Differentiated Neuroendocrine Carcinoma of the Lung and Thymus - LUNA Trial Completed NCT01563354 Phase 2 Pasireotide LAR;Everolimus;Pasireotide LAR and Everolimus Combination
38 A Pilot Study of Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated Grade 3 Neuroendocrine Carcinomas Completed NCT03278405 Phase 1, Phase 2 Avelumab
39 A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing After First-Line Platinum- Based Therapy Completed NCT04122911 Phase 2 Temozolomide
40 An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Poorly Differentiated Neuroendocrine Carcinomas Completed NCT02457273 Phase 2 TLC 388
41 An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment. Completed NCT02955069 Phase 2 PDR001
42 A Phase II Study of Irinotecan and Cisplatin for Metastatic or Unresectable High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract Completed NCT00353015 Phase 2 Cisplatin;Irinotecan
43 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
44 A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung Completed NCT02936323 Phase 1, Phase 2 PEN-221
45 A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00780663 Phase 2 Quarfloxin
46 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
47 A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
48 Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
49 Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2 Selinexor
50 A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy. Completed NCT01788982 Phase 2 Nintedanib;Placebo

Search NIH Clinical Center for Neuroendocrine Carcinoma

Cochrane evidence based reviews: carcinoma, neuroendocrine

Genetic Tests for Neuroendocrine Carcinoma

Anatomical Context for Neuroendocrine Carcinoma

MalaCards organs/tissues related to Neuroendocrine Carcinoma:

40
Thyroid, Breast, Cervix, Prostate, Skin, Pancreas, Liver

Publications for Neuroendocrine Carcinoma

Articles related to Neuroendocrine Carcinoma:

(show top 50) (show all 4557)
# Title Authors PMID Year
1
Large cell neuroendocrine carcinoma with sarcomatous changes of the endometrium: a case report with immunohistochemical studies and molecular genetic study of KIT and PDGFRA. 61 54
20189318 2010
2
An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63. 54 61
20182342 2010
3
Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. 61 54
20398190 2010
4
Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. 61 54
19859629 2009
5
The expression and diagnostic utility of p63 in the female genital tract. 61 54
19700941 2009
6
Expression of Notch-1 and alteration of the E-cadherin/beta-catenin cell adhesion complex are observed in primary cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). 61 54
19396152 2009
7
A limited immunohistochemical panel helps differentiate small cell epithelial malignancies of the sinonasal cavity and nasopharynx. 61 54
19077909 2009
8
Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine carcinoma of uterine cervix. 61 54
18726606 2009
9
Cutaneous metastasis from large-cell neuroendocrine carcinoma of the urinary bladder expressing CK20 and TTF-1. 54 61
19318803 2009
10
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. 61 54
19139719 2009
11
Frequent expression of glypican-3 in Merkel cell carcinoma: an immunohistochemical study of 55 cases. 61 54
18813128 2009
12
Monoclonality of composite large cell neuroendocrine carcinoma and mucinous epithelial tumor of the ovary: a case study. 61 54
19047907 2009
13
Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? 61 54
18360283 2008
14
Primary male neuroendocrine adenocarcinoma involving the nipple simulating Merkel cell carcinoma - a diagnostic pitfall. 61 54
18190447 2008
15
Differential expression of neural-cadherin in pulmonary epithelial tumours. 54 61
18269586 2008
16
Association of malignant insulinoma and type 2 diabetes mellitus: a case report. 61 54
18291348 2008
17
Clinical implications of unusual NeuroD and mASH1 expression in a patient with primary large-cell neuroendocrine carcinoma of the duodenum: report of a case. 61 54
18751955 2008
18
Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung. 54 61
18091382 2007
19
Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers. 61 54
17066436 2007
20
Medical treatment of gastrinomas. 54 61
17985097 2007
21
Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? 54 61
16798833 2007
22
Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. 54 61
16862075 2006
23
Tumor of the liver (hepatocellular and high grade neuroendocrine carcinoma): a case report and review of the literature. 61 54
16896889 2006
24
[Clinicopathologic characteristics of colorectal neuroendocrine tumor]. 54 61
16929153 2006
25
Composite adenocarcinoma and large cell neuroendocrine carcinoma of the rectum. 61 54
16508780 2006
26
Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium. 61 54
16681768 2006
27
CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. 61 54
16119980 2005
28
Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver. 61 54
16078249 2005
29
Cytokeratin 20-positive large cell neuroendocrine carcinoma of the colon. 61 54
15998383 2005
30
Carcinosarcoma of the liver: a case report and review of the literature. 61 54
15913431 2005
31
Duodenal somatostatinoma: clinical and immunohistochemical patterns--difficult differential diagnosis in regard to gangliocytic paraganglioma: report of a case. 54 61
15851380 2005
32
Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors. 54 61
15722802 2005
33
Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molecular genetic study. 54 61
15381906 2004
34
Ovarian non-small cell neuroendocrine carcinoma with paraneoplastic parathyroid hormone-related hypercalcemia. 54 61
15381910 2004
35
Thyroid transcription factor-1, but not p53, is helpful in distinguishing moderately differentiated neuroendocrine carcinoma of the larynx from medullary carcinoma of the thyroid. 61 54
15098009 2004
36
Comparative study of primary mammary small cell carcinoma, carcinoma with endocrine features and invasive ductal carcinoma. 61 54
15010880 2004
37
Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. 54 61
15047210 2004
38
hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. 61 54
14657947 2004
39
The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. 54 61
14726070 2004
40
Diagnostic value of microtubule-associated protein-2 in Merkel cell carcinoma. 54 61
14663358 2003
41
Analysis of protein expression and gene mutation of c-kit in colorectal neuroendocrine carcinomas. 54 61
14657715 2003
42
Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. 61 54
12711118 2003
43
Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. 54 61
12733148 2003
44
Diagnostic value of microtubule-associated protein-2 (MAP-2) for neuroendocrine neoplasms. 54 61
12605092 2003
45
Neuroendocrine tissue-specific transcription factor, BETA2/NeuroD, in gastric carcinomas: a comparison with chromogranin A and synaptophysin expressions. 61 54
14533935 2003
46
Histidine decarboxylase expression as a new sensitive and specific marker for small cell lung carcinoma. 54 61
12527716 2003
47
[Intraarterial neoadjuvant chemotherapy with cisplatin effective against neuroendocrine carcinoma of the urinary bladder: a case report]. 54 61
12229180 2002
48
Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. 61 54
11567220 2001
49
Primary mesenteric malignant mixed mesodermal (müllerian) tumor with neuroendocrine differentiation. 54 61
11353063 2001
50
Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. 61 54
11381365 2001

Variations for Neuroendocrine Carcinoma

Copy number variations for Neuroendocrine Carcinoma from CNVD:

7 (show all 16)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 46474 10 81600000 81900000 Gain or loss TMEM254 Neuroendocrine carcinoma
2 46475 10 81600000 81900000 Gain or loss PLAC9 Neuroendocrine carcinoma
3 46476 10 81600000 81900000 Gain or loss SFTPD Neuroendocrine carcinoma
4 98126 16 15400000 16800000 Duplication ABCC1 Neuroendocrine carcinoma
5 98127 16 15400000 16800000 Duplication ABCC6 Neuroendocrine carcinoma
6 98128 16 15400000 16800000 Duplication BMERB1 Neuroendocrine carcinoma
7 98129 16 15400000 16800000 Duplication CEP20 Neuroendocrine carcinoma
8 98130 16 15400000 16800000 Duplication MARF1 Neuroendocrine carcinoma
9 98131 16 15400000 16800000 Duplication MYH11 Neuroendocrine carcinoma
10 98132 16 15400000 16800000 Duplication NDE1 Neuroendocrine carcinoma
11 109503 17 26446120 26728821 Microdeletion NF1 Neuroendocrine carcinoma
12 111157 17 35097918 35138441 Gain ERBB2 Neuroendocrine carcinoma
13 122931 18 64000000 64040000 Deletion Neuroendocrine carcinoma
14 160839 22 16300000 24300000 Microdeletion Neuroendocrine carcinoma
15 226129 7 55054218 55242525 Gain EGFR Neuroendocrine carcinoma
16 248801 9 137300000 137400000 Duplication LINC02907 Neuroendocrine carcinoma

Expression for Neuroendocrine Carcinoma

Search GEO for disease gene expression data for Neuroendocrine Carcinoma.

Pathways for Neuroendocrine Carcinoma

Pathways related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 SYP NKX2-1 NCAM1 ENO2 CALCA
2 11.34 PTEN PDGFRA KIT
3 11.06 PDGFRA NCAM1 KIT
4 10.92 SYP PDGFRA NCAM1 FGFR4 ASCL1
5 10.1 GRP GAST

GO Terms for Neuroendocrine Carcinoma

Cellular components related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 SST MUC1 KIT GRP GAST ENO2
2 extracellular region GO:0005576 9.28 SST PTEN NCAM1 MUC1 GRP GAST

Biological processes related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of kinase activity GO:0033674 9.5 PDGFRA KIT FGFR4
2 positive regulation of phospholipase C activity GO:0010863 9.43 PDGFRA KIT
3 Leydig cell differentiation GO:0033327 9.4 PDGFRA NKX2-1
4 forebrain neuron differentiation GO:0021879 9.37 NKX2-1 ASCL1
5 mast cell chemotaxis GO:0002551 9.26 KIT CHGA
6 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.16 GRP CHGA
7 cerebral cortex GABAergic interneuron differentiation GO:0021892 8.96 NKX2-1 ASCL1
8 mast cell cytokine production GO:0032762 8.62 KIT CHGA

Molecular functions related to Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 PDGFRA KIT FGFR4

Sources for Neuroendocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....